Core Viewpoint - Tandem Diabetes Care, Inc. has announced the pricing of $265.0 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2032 in a private placement aimed at qualified institutional buyers under Rule 144A of the Securities Act [1] Group 1 - The offering of the convertible senior notes was upsized from a previously announced amount [1]

Core Insights - Globus Medical reported revenue of $826.42 million for the quarter ended December 2025, reflecting a year-over-year increase of 25.7% and surpassing the Zacks Consensus Estimate by 4.9% [1] - The company's EPS for the quarter was $1.28, up from $0.84 in the same quarter last year, resulting in an EPS surprise of 20.76% compared to the consensus estimate of $1.06 [1] Revenue Breakdown - International revenues reached $161.1 million, exceeding the average estimate of $147.72 million by analysts, marking a 19% increase year-over-year [4] - U.S. revenues totaled $665.32 million, surpassing the average estimate of $621.92 million, with a year-over-year growth of 27.5% [4] Product Category Performance - Net sales from Enabling Technologies were $55.62 million, exceeding the average estimate of $33.7 million, representing an 18.5% increase year-over-year [4] - Net sales from Musculoskeletal Solutions amounted to $770.8 million, above the average estimate of $735.95 million, showing a year-over-year growth of 26.3% [4] Stock Performance - Shares of Globus Medical have returned +0.5% over the past month, while the Zacks S&P 500 composite has decreased by -1%, indicating potential outperformance in the near term [3]

Core Insights - Alcon reported $2.7 billion in revenue for Q4 2025, marking a year-over-year increase of 9.1% and an EPS of $0.78, up from $0.72 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate by 0.2%, while the EPS also missed the consensus estimate by 0.76% [1] Financial Performance Metrics - Total Surgical Equipment/Other net sales were $277 million, a 21% increase year-over-year, but slightly below the average estimate of $277.54 million [4] - Total Surgical Implantables net sales reached $474 million, reflecting a 4% year-over-year increase, but below the estimated $482.1 million [4] - Total Surgical net sales amounted to $1.55 billion, an 8.6% year-over-year increase, slightly under the average estimate of $1.56 billion [4] - Total Vision Care net sales were $1.16 billion, a 9.8% increase year-over-year, exceeding the average estimate of $1.15 billion [4] - Total Surgical Consumables net sales were $794 million, a 7.6% year-over-year increase, just below the average estimate of $796.13 million [4] - Total Vision Care Contact Lenses net sales were $683 million, a 7.1% increase year-over-year, slightly below the average estimate of $687.14 million [4] - Total Vision Care Ocular Health net sales reached $474 million, a 13.9% year-over-year increase, surpassing the average estimate of $462.7 million [4] - Other revenues were reported at $16 million, a significant decline of 36% year-over-year, and below the estimated $26.18 million [4] - Overall net sales matched the average estimate of $2.7 billion [4] Stock Performance - Alcon shares have returned +2.6% over the past month, outperforming the Zacks S&P 500 composite, which saw a -1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 from $78 while maintaining an Outperform rating, citing a favorable post-earnings setup following a quarterly beat that exceeded expectations. The previous day, DexCom, Inc. (NASDAQ:DXCM) reported fourth-quarter revenue of $1.26 billion, slightly above the $1.25 billion consensus estimate. Management highli ...

For the quarter ended December 2025, Merit Medical (MMSI) reported revenue of $393.94 million, up 10.9% over the same period last year. EPS came in at $1.04, compared to $0.93 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $390.83 million, representing a surprise of +0.8%. The company delivered an EPS surprise of +8.9%, with the consensus EPS estimate being $0.96.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Positioned the platform to address the 'acute brain failure' of delirium, targeting a $1 billion greenfield market where no other FDA-cleared monitoring device exists.Maintained high gross margins of 88% for the full year through manufacturing efficiencies and a strategic transition to a Vietnam-based production line.Leveraged FedRAMP High authorization to unlock the 170-hospital VA system, transitioning from a successful pilot to active system-wide expansion.Increased commercial infrastructure to 55 territ ...

Management also addressed an apparent shift in quarterly patterns. Koning said momentum in deformity contributed to stronger volumes in the second and third quarters of 2025, which reduced the typical sequential jump in the fourth quarter. “What initially looks like deceleration is masking underlying momentum,” he said.In the U.S., same-store sales in established territories grew 20% year-over-year. EOS revenue grew 14% year-over-year to $23 million .Surgical revenue grew 21% year-over-year and 7% sequentia ...

Inogen (NasdaqGS:INGN) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Company ParticipantsAnderson Schock - MedTech Equity Research AssociateJoseph Conway - Equity Research AssociateKevin Smith - President and CEOLauren Williams - Senior VP of Investor Relations and Strategic PlanningMike Bourque - CFOOperatorWelcome to Inogen's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To as ...

Inogen (NasdaqGS:INGN) Q4 2025 Earnings call February 24, 2026 05:00 PM ET Speaker5Welcome to Inogen's fourth quarter 2025 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star, followed by the number 1 on your touchtone phone. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference is being rec ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - February 24, 2026) - Faru ...